Medicinova Stock Performance
| MNOV Stock | USD 1.55 0.05 3.33% |
The company secures a Beta (Market Risk) of 0.74, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, MediciNova's returns are expected to increase less than the market. However, during the bear market, the loss of holding MediciNova is expected to be smaller as well. At this point, MediciNova has a negative expected return of -0.56%. Please make sure to verify MediciNova's maximum drawdown, as well as the relationship between the daily balance of power and relative strength index , to decide if MediciNova performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days MediciNova has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
Last Split Factor 1:10 | Last Split Date 2006-10-31 |
1 | MediciNova Stock Passes Above 200-Day Moving Average - Heres What Happened - MarketBeat | 01/02/2025 |
2 | Acquisition by Matsuda Kazuko of 300000 shares of MediciNova at 1.52 subject to Rule 16b-3 | 01/07/2025 |
3 | MediciNova Share Price Crosses Above 200 Day Moving Average - Should You Sell - MarketBeat | 01/10/2025 |
4 | Type 2 Diabetes Market Poised for Remarkable Growth by 2034, Reveals DelveInsight | 01/15/2025 |
5 | US Exchange Penny Stocks To Watch In January 2025 | 01/28/2025 |
6 | Acquisition by Okajima Masatsune of 100000 shares of MediciNova at 6.1 subject to Rule 16b-3 | 01/31/2025 |
7 | Global Microtome Market to Exhibit Growth at a CAGR of 6 percent by 2032 DelveInsight | 02/19/2025 |
8 | Disposition of 15000 shares by Nagao Hideki of MediciNova at 2.58 subject to Rule 16b-3 | 02/20/2025 |
9 | Acquisition by Iwaki Yuichi of 235125 shares of MediciNova subject to Rule 16b-3 | 03/04/2025 |
10 | Disposition of 1000 shares by Nagao Hideki of MediciNova at 2.77 subject to Rule 16b-3 | 03/05/2025 |
11 | MediciNova Research Coverage Started at StockNews.com | 03/10/2025 |
| Begin Period Cash Flow | 51 M |
MediciNova |
MediciNova Relative Risk vs. Return Landscape
If you would invest 216.00 in MediciNova on December 19, 2024 and sell it today you would lose (66.00) from holding MediciNova or give up 30.56% of portfolio value over 90 days. MediciNova is currently does not generate positive expected returns and assumes 3.0304% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than MediciNova, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MediciNova Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MediciNova's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MediciNova, and traders can use it to determine the average amount a MediciNova's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1849
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MNOV |
Estimated Market Risk
| 3.03 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.56 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average MediciNova is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MediciNova by adding MediciNova to a well-diversified portfolio.
MediciNova Fundamentals Growth
MediciNova Stock prices reflect investors' perceptions of the future prospects and financial health of MediciNova, and MediciNova fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MediciNova Stock performance.
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 35.37 M | ||||
| Shares Outstanding | 49.05 M | ||||
| Price To Earning | (24.69) X | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 82.89 X | ||||
| EBITDA | (12.65 M) | ||||
| Net Income | (11.05 M) | ||||
| Cash And Equivalents | 65.23 M | ||||
| Cash Per Share | 1.33 X | ||||
| Total Debt | 3.37 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.17 X | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | (10.64 M) | ||||
| Earnings Per Share | (0.23) X | ||||
| Market Capitalization | 73.57 M | ||||
| Total Asset | 55.88 M | ||||
| Retained Earnings | (426.75 M) | ||||
| Working Capital | 38.12 M | ||||
| Current Asset | 22.73 M | ||||
| Current Liabilities | 1.49 M | ||||
About MediciNova Performance
Evaluating MediciNova's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if MediciNova has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MediciNova has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.14) | (0.15) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.12) | (0.13) |
Things to note about MediciNova performance evaluation
Checking the ongoing alerts about MediciNova for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MediciNova help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MediciNova generated a negative expected return over the last 90 days | |
| MediciNova may become a speculative penny stock | |
| MediciNova has high historical volatility and very poor performance | |
| Net Loss for the year was (11.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MediciNova currently holds about 65.23 M in cash with (10.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.33. | |
| MediciNova has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: MediciNova Research Coverage Started at StockNews.com |
- Analyzing MediciNova's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MediciNova's stock is overvalued or undervalued compared to its peers.
- Examining MediciNova's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MediciNova's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MediciNova's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MediciNova's stock. These opinions can provide insight into MediciNova's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.